Drug Combination Details
| General Information of the Combination (ID: C61395) | |||||
|---|---|---|---|---|---|
| Name | Orientin NP Info | + | BS21 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Obesity
[ICD-11: 5B81]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | ACACA | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CEBPA | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CHPT1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | FABP4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | FAS | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PPAR-gamma | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PPARGC1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PRDM16 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SREBF1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | UCP1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | UCP2 | Molecule Info | |||
| In-vitro Model | 3T3-L1 | CVCL_0123 | Healthy | Mus musculus | ||
| Experimental
Result(s) |
BS21 plays a modulatory role in adipocytes by reducing adipogenesis and lipogenesis, increasing fat oxidation, and inducing browning. | |||||
